Clinical Trial

Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases

Study acronym: EPPIK
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To evaluate the safety, efficacy and tolerability of sparsentan oral suspension and tablets, and assess changes in proteinuria after once-daily dosing over 108 weeks.
Protocol Amendment History 27 amendments
This ClinicalTrials.gov record has been amended 27 times since 2021-08-04; most recent amendment 2026-05-08.
Status change: Not Yet Recruiting → Recruiting 2021-08-13
Trial Details
NCT Number NCT05003986
Lead Sponsor Travere Therapeutics, Inc.
Conditions Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis, Alport Syndrome
Enrollment 67 participants
Start Date 2021-08-12
Primary Completion 2027-03-12 (estimated)
Study Completion 2027-04-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-12